Johnson & Johnson (JNJ) Tops Q2 EPS by 6c; Boosts FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BMO Capital Reiterates Outperform on Johnson & Johnson (JNJ) Following 2Q Report
July 20, 2016 10:39 AM EDTBMO Capital reiterated an Outperform rating and $132.00 price target on Johnson & Johnson (NYSE: JNJ) following the company's 2Q earnings report. JNJ reported revenue of $18.48B, ahead of the consensus estimate of $17.98 billion. EPS of $1.74 was also above the consensus estimates at $1.68.
Analyst Joanne... More
